Lipella Pharmaceuticals Earnings Date & Estimates

Lipella Pharmaceuticals (NASDAQ:LIPO) is a clinical-stage biotechnology company focused on developing localized treatments for diseases with significant unmet medical needs. The company’s research centers on liposomal drug-delivery technologies designed to deliver therapeutic agents directly to affected tissues while potentially limiting systemic exposure.

Lipella’s lead candidate, LP-10, is an intravesical liposomal formulation of tacrolimus being developed for hemorrhagic cystitis, a painful bladder condition that can occur following cancer treatment. The company has also advanced LP-310, an oral liposomal formulation intended for the treatment of inflammatory and mucosal diseases of the mouth, including oral mucositis.

Based in Pittsburgh, Pennsylvania, Lipella conducts its development activities primarily in the United States and focuses on advancing therapies through clinical and regulatory evaluation. The company’s programs are aimed at conditions affecting the bladder and oral cavity, where localized delivery may offer advantages over conventional systemic treatments.